Back to User profile » Prof. Dr. Henriette Meyer zu Schwabedissen
Papers published by Prof. Dr. Henriette Meyer zu Schwabedissen:
Population-Based Assessment of Phenoconversion Potential in Switzerland: A Claims Data Study of Key Drug-Metabolizing Enzymes and Transporters
Roth MM, Bencastro A, Meier CR, Huber CA, Meyer zu Schwabedissen HE, Allemann SS, Schneider C
Pharmacogenomics and Personalized Medicine 2026, 19:586384
Published Date: 20 May 2026
A Swiss Cross-Sectional Study on Patients’ Perspectives on Chronic Pain Management, Analgesic Treatment, and Genetic Susceptibility
Bollinger A, Stäuble CK, Urdieux IO, Meyer zu Schwabedissen HE, Allemann SS
Journal of Pain Research 2025, 18:4575-4587
Published Date: 5 September 2025
The Prevalence of Potential Drug-Drug-Gene Interactions: A Descriptive Study Using Swiss Claims Data
Wittwer NL, Meier CR, Huber CA, Moser JD, Meyer zu Schwabedissen HE, Allemann SS, Schneider C
Pharmacogenomics and Personalized Medicine 2025, 18:197-208
Published Date: 23 August 2025
Genotyping of Patients with Adverse Drug Reaction or Therapy Failure: Database Analysis of a Pharmacogenetics Case Series Study
Bollinger A, Stäuble CK, Jeiziner C, Wiss FM, Hersberger KE, Lampert ML, Meyer zu Schwabedissen HE, Allemann SS
Pharmacogenomics and Personalized Medicine 2023, 16:693-706
Published Date: 3 July 2023
Utilization of Drugs with Pharmacogenetic Dosing Recommendations in Switzerland: A Descriptive Study Using the Helsana Database
Wittwer NL, Meier CR, Huber CA, Meyer zu Schwabedissen HE, Allemann S, Schneider C
Pharmacogenomics and Personalized Medicine 2022, 15:967-976
Published Date: 23 November 2022
Is Pharmacogenetic Panel Testing Applicable to Low-Dose Methotrexate in Rheumatoid Arthritis? – A Case Report
Jeiziner C, Allemann SS, Hersberger KE, Meyer zu Schwabedissen HE
Pharmacogenomics and Personalized Medicine 2022, 15:465-475
Published Date: 9 May 2022
Enriching Medication Review with a Pharmacogenetic Profile – A Case of Tamoxifen Adverse Drug Reactions
Jeiziner C, Stäuble CK, Lampert ML, Hersberger KE, Meyer zu Schwabedissen HE
Pharmacogenomics and Personalized Medicine 2021, 14:279-286
Published Date: 19 February 2021
Modulation of expression of the nuclear receptor NR0B2 (small heterodimer partner 1) and its impact on proliferation of renal carcinoma cells
Prestin K, Olbert M, Hussner J, Isenegger TL, Gliesche DG, Böttcher K, Zimmermann U, Meyer zu Schwabedissen HE
OncoTargets and Therapy 2016, 9:4867-4878
Published Date: 8 August 2016